Figure 5. Increased serum concentrations of TIMP-4 and Endoglin and decreased levels of pentraxin-3 in CF patients with liver disease.
In the whole CF cohort, patients with CFLD (n = 17) exhibited significantly higher serum levels of TIMP-4 and Endoglin than patients without liver disease (n = 28). Pentraxin-3 serum levels were significantly decreased in patients with CFLD whereas serum concentration of hepatocyte growth factor (HGF) was unchanged between CF patients with and without CFLD.
